CLINICAL_TRIALS
withdrawal
· 2017-02-17
Clinical Trial Update: Sulindac for Patients With AML [Phase 2]
Summary
The Phase 2 clinical trial of sulindac for acute myeloid leukemia has been withdrawn.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Massachusetts General Hospital | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: WITHDRAWN